Brought to you by 
United Therapeutics gets rights to Lilly's tadalafil for PAH
29 Apr 2015
Executive Summary
Eli Lilly has granted United Therapeutics (focuses on oncology, cardiovascular, and infectious diseases) exclusive rights to sell tadalafil (currently on the market as Cialis for erectile dysfunction) in the US and Puerto Rico for pulmonary arterial hypertension (PAH).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
United Therapeutics gets rights to Lilly's tadalafil for PAH
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice